1. Home
  2. NSRX vs BHST Comparison

NSRX vs BHST Comparison

Compare NSRX & BHST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nasus Pharma Ltd. Ordinary Shares

NSRX

Nasus Pharma Ltd. Ordinary Shares

HOLD

Current Price

$3.09

Market Cap

38.9M

Sector

Health Care

ML Signal

HOLD

BHST

BioHarvest Sciences Inc.

SELL

Current Price

$1.66

Market Cap

41.3M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
NSRX
BHST
Founded
2019
2007
Country
Israel
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.9M
41.3M
IPO Year
2024
2017

Fundamental Metrics

Financial Performance
Metric
NSRX
BHST
Price
$3.09
$1.66
Analyst Decision
Buy
Strong Buy
Analyst Count
2
4
Target Price
★ $19.67
$10.50
AVG Volume (30 Days)
21.1K
★ 22.5K
Earning Date
08-17-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$8.44
Revenue Next Year
N/A
$32.53
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.98
$1.37
52 Week High
$9.50
$12.20

Technical Indicators

Market Signals
Indicator
NSRX
BHST
Relative Strength Index (RSI) 34.65 51.05
Support Level $2.97 $1.40
Resistance Level $3.60 $1.77
Average True Range (ATR) 0.25 0.12
MACD -0.07 0.05
Stochastic Oscillator 10.94 64.82

Price Performance

Historical Comparison
NSRX
BHST

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

About BHST BioHarvest Sciences Inc.

BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. The Company has two operating segments or business units: the Products business unit and the CDMO Services business unit. In identifying these operating segments, management generally follows the Company's service lines representing its main products and services. The Products Business Unit - Nutraceuticals: Research, development, manufacturing, marketing and sales of science-based health and wellness nutraceutical solutions which are manufactured and sold as dietary supplements, functional food and beverages. The CDMO Services Business Unit - comprising a Contract Development and Manufacturing Operation that offers pharmaceuticals, cosmeceuticals, nutraceuticals, and nutritions.

Share on Social Networks: